Semagludite: The cause for NAION and Blood Clots?

Last Updated on November 4, 2024 by Joseph Gut – thasso

November 02, 2024 – In the popular press and with people of public interest and fame in the weightloss and beauty industries, Semaglutide has been considered the slimming miracle elixir par excellence. Wegovy, Rybelsus, and Ozempic, all of which are based on their common active ingredient Semaglutide may work for some patients as promoted and intended, with some spectacular weight loss results in some mostly prominent individuals.

However; there are some serious health risks, i.e. serious adverse drug reactions (sADR), associated with these drugs, which are rarely mentioned or addressed in the euphoric press releases. Such rare but serious side effects may occur with the Semaglutide drugs and include, among others, a) Severe Allergic Reactions which can be serious, b) Thyroid Tumors of which some could be cancerous, c) Pancreatitis including vomiting or severe pain in the upper part of the belly travelling to the back, d) Gallbladder Problems  including cholecystitis and cholelithiasis (i.e. gallstones) and also jaundice, e) Low Blood Sugar (Hypoglycemia), especially when used with insulin , and f) Kidney Damage. Moreover, with Wegovy, Fast Heart Rate (Tachycardia) and Suicidal Thoughts and Actions have been reported by a small number of people.

Furthermore, recent reports on Wegovy-, Rybelsus-, and Ozempi-dependent eye side effects have appeared and are most likely linked to the fact that recent findings indicate that the active ingredient of these three drugs Semaglutide is associated with the development of nonarteritic anterior ischemic optic neuropathy (NAION).

As background, NAION, sometimes referred to as an “eye stroke,” develops from insufficient blood flow to the optic nerve and causes sudden painless vision loss in one eye. It is the second most common cause of blindness due to optic nerve damage, after glaucoma. An observational study on [July 3, 2024] reported for the first time a potential link between Novo Nordisk’s GLP-1 drugs Ozempic and Wegovy and an eye condition that can cause vision loss.

After hearing anecdotes of patients on the diabetes and obesity drugs experiencing nonarteritic anterior ischemic optic neuropathy, or NAION, researchers analyzed data from a registry of patients at their institution to see if there was a broad trend. In both the diabetes and obesity cohorts that got semaglutide, the researchers found that NAION cases occurred most frequently in the first year after the medications were prescribed. NAION occurs from a lack of sufficient blood flow to the optic nerve. There are currently no proven treatments for the condition.

Besides NAION-cases, a growing number of pulmonary embolism and deep vein thrombosis (DVT)  cases involving Semaglutide are reported by patients. Thus, it seems that the Semaglutide-drugs Wegovy, Rybelsus, and Ozempic are associated with an increased risk of blood clots that can lead to pulmonary embolism  and deep vein thrombosis (DVT). However, there are no warnings about blood clots in the current prescribing informations (i.e., drug labels) of  Ozempic, Wegovy, and Rybelsus .

Even though in January 2024, the U.S. Food and Drug Administration (FDA) said that it is investigating cases of hair loss, aspiration (when food or other objects get into airways), and suicidal ideation in people who use Semaglutide medications, apparently blood clouds under Semaglutide where not (yet) a topic. But, in a journal article in 2021 in the Endocrine Journal, the effect of Sematiglide on blood clot formation became evident from the

results in the SUSTAIN and PIONEER clinical trials, where an apparent increase in Semaglutide-dependent blood clots as cause for deep vein thrombosis (DVT) was noted. Despite of these findings, this Semaglutide side effect has not yet garnered a lot of attention, although it may turn out life threatening if not fatal in patients affected.

This definitively needs to be addressed by regulatory authorities and the super optimistic media in order to provide a realistic spectrum on the effect (positive and/or negative ) of these miraculous wonder slimming pills, respective injections.

Note that Tasso had already in the past addressed some of these aspects here, here, here, here, and here, surrounding slimming pills; Unfortunately, there is not yet information on the genetic predisposition of patient under Semaglutide for any of the many sADR, which would be at the basic interest of Thasso. See also here a short sequence on some (mis)information on Ozempic in this case:

Disclaimer: Images and/or videos (if any) in this blog may be copyrighted. All rights remain with the owner of such rights.